Mylan is seeking at 3-4 billion purchase in generic space and also seeking Proprietary addions= IPXL
This move would make more sense than anything. May already be in the Works and talks with JPM due to the pathetic Golman rating on this company. It was laughable and I believe those not in the deal loop have reacted in anger instead of objective ratings like they should have. Holders of this stock stand to be well rewarded as it isn't well followed yet holds a power punch of potential.
Could be Mylan, Pfizer or even GSK due to the prorietary developments unfolding. I think a mid $40 offer fair value when you add up the parts and potential of the Rytary approval that is forthcoming. Next few weeks should be exciting for the company. Obviously something big is in the works evidenced by the spat of ratings and price upgrades.
No deal for foreseeable future. Larry has all the money he needs and wants to see how far this company can go on its own. With Rytary approval, this stock can grow in leaps and bounds. Several other branded products on the slate through acquisitions. This drop after earnings is a gift for the LT investor of IPXL.